Fig. 4
Niclosamide inhibits TFH-like cell differentiation and B cell IgG production in vitro. Naive CD4+ T cells were purified from the spleens of MRL/lpr and C57BL/6 mice. For TFH-like cell differentiation, purified CD4+ T cells were activated with mouse T-activator CD3/CD28 Dynabeads, and treated with 20 ng/ml IL-6, 20 ng/ml IL-21, 10 μg/ml anti-IL-4, 10 μg/ml anti-IFN-γ, and 20 μg/ml anti-TGF-β for 4 days with or without niclosamide. a Left, TFH-like cells (CXCR5+PD-1+, gated on CD4+) isolated from MRL/lpr mice were analyzed by flow cytometry. Right, the percentage of TFH-like cells is shown. b p-STAT3 and TCF-1 expressions in TFH-like cells isolated from MRL/lpr mice were analyzed by western blot. c mRNA expression levels of Bcl-6, CXCR5, and Blimp-1 in TFH-like cells isolated from MRL/lpr mice were measured by real-time PCR. d TFH-like cells and B cells isolated from C57BL/6 mice were co-cultured with or without TFH-like cells for 3 days, and then the concentrations of IgG in the supernatants were detected by ELISA. Data shown as mean ± SD. One-way ANOVA was performed. **P < 0.01, ***P < 0.001, ****P < 0.0001, ns: not significant